Gastroesophageal Cancers | Meet The Professor: Optimizing the Management of Gastroesophageal Cancers — Part 5

Featuring perspectives from Dr John Strickler, including the following topics:

• Introduction (0:00)
• Case: A man in his early 60s with gastroesophageal junction (GEJ) adenocarcinoma who responds to neoadjuvant chemoradiation therapy but declines surgery and develops progressive disease (HER2 1+, PD-L1 2%) — Minesh Dinubhai Patel, MD (13:54)
• Case: A frail woman in her late 80s with unresectable gastric cancer who chooses to receive systemic therapy (PD-L1 0%, HER2 negative, MSS) — Matthew R Strickland, MD (18:20)
• Case: A man in his mid 60s with T3N1M mixed gastric adenocarcinoma who responds well to neoadjuvant FLOT and has minimal residual disease at surgery — Ranju Gupta, MD (23:01)
• Case: A man in his early 60s with a history of prostate cancer who is now diagnosed with T2N1M0, HER2-positive GEJ adenocarcinoma — Dr Strickland (29:23)
• Case: A man in his early 30s with metastatic HER2-positive gastric adenocarcinoma who is responding well to FOLFOX, trastuzumab and nivolumab — Priya Rudolph, MD, PhD (33:00)
• Case: A man in his early 60s with metastatic HER2-positive esophageal cancer and a germline CHEK2 mutation who experiences disease progression on chemotherapy, pembrolizumab, trastuzumab and later T-DXd (PD-L1 12%) — Warren S Brenner, MD (46:34)
• Case: A man in his mid 70s with symptomatic anemia who is diagnosed with metastatic esophageal adenocarcinoma (PD-L1 8%, MSS, HER2 1+) — Dr Strickland (55:44)
• Case: A woman in her early 60s with squamous cell esophageal carcinoma metastatic to bone (PD-L1 TPS 10%) — Dr Strickland (58:46)

CME information and select publications